Despite the evidence that cervical vaginal screening has reduced the number of women who die of cervical cancer in the United States, 12,800 women are diagnosed yearly with cervical cancer, and 4,600 die of the disease. 1 Efforts to decrease the incidence of cervical cancer have been targeted on screening women who have not been screened or have been screened infrequently and on new cytologic methods to increase detection rates of squamous intraepithelial lesions (SILs). [2] [3] [4] [5] [6] [7] Less study has been targeted on other methods of error reduction in cervical cancer screening and on the contribution of clinical mismanagement (ie, clinical rather than laboratory error) to the incidence of cervical cancer.
A portion of clinical error results from the misinterpretation of laboratory data. 8, 9 Powsner et al 10 reported that surgeons misunderstood 30% of pathology reports and that streamlined report formats actually exacerbated the problem. Dawson and Arkes 8 reported that for many clinicians, cognitive biases lead to difficulties in estimating disease probabilities. In regard to cervical cancer screening, Baldauf et al 11 reported that 35.6% of women who had a cervical vaginal smear diagnosis of high-grade SIL were mismanaged clinically. Ferris et al 12 reported that 12% of physicians thought that colposcopic examination was unnecessary for women who had a high-grade SIL diagnosis. These figures persist despite the publication of clinical practice guidelines.
Although it has been shown that some physicians think that the Bethesda System reporting format reduces patient management errors, others have suggested, as Powsner et al 10 implied, that clinical mismanagement may have increased as a result of the widespread use of Bethesda System reporting formats. 13, 14 The clinical understanding of specific Bethesda System diagnoses is largely unknown. It is unclear whether clinicians understand the disease probabilities associated with Bethesda System diagnoses and whether a lack of understanding leads to clinical mismanagement. If a misunderstanding exists, reparative attempts could be made through changes in report formats.
In the present study, using survey methods, we measured the clinical estimation of disease probability associated with specific Bethesda System diagnoses. These estimations were correlated with published values to determine the percentage of clinicians who were outliers.
Materials and Methods
A questionnaire that measured clinician demographics and estimates of probability of disease or no disease associated with specific Bethesda System cervical vaginal diagnoses was prepared and administered by the Division of Clinical Effectiveness, Allegheny General Hospital, Pittsburgh, PA. 15, 16 A pilot questionnaire was tested initially on a convenience sample of 50 obstetrician/gynecologists (OGYNs) in Pennsylvania 15, 16 ; the names of these OGYNs were obtained from the Pennsylvania State Board of Medicine. Based on their responses and general comments about the questionnaire, a final questionnaire was prepared.
The final questionnaire used in the present study consisted of 2 pages. The first page measured clinician demographics by asking 5 questions about specialty (ie, OGYN or other primary care [PCP]), type of practice (ie, academic or private practice), years in practice, number of cervical vaginal samples obtained per month, and number of colposcopic examinations ordered or performed per month. Other PCPs predominantly consisted of family practitioners. This part of the questionnaire also included 3 questions about liquid-based cytology; the clinicians were asked whether they used liquid-based cytology, whether they thought liquid-based cytology increased the sensitivity of detection of dysplastic lesions, and whether they thought liquid-based cytology was cost-effective. For each of these 3 questions, the clinician could answer yes, no, or unsure.
In the second part of the questionnaire, clinicians were asked to complete a table correlating specific Bethesda System diagnoses with probability of disease or no disease. 17 The clinicians were asked to assume that they had obtained a cervical vaginal sample on a 30-year-old white woman who had no history of cervical vaginal disease and who had a negative cervical vaginal sample 12 months before the current cervical vaginal sample. To some extent, this scenario set the pretest probability of disease. The Bethesda System diagnoses listed in the table were within normal limits, reactive changes, atypical squamous cell of undetermined significance (ASCUS), atypical glandular cells of undetermined significance (AGUS), low-grade SIL, high-grade SIL, and invasive carcinoma. 18 For each Bethesda System diagnosis, clinicians estimated the probability of no disease (ie, no cervical intraepithelial neoplasia [CIN] or invasive carcinoma), CIN 1 (ie, mild dysplasia), CIN 2 or 3 (ie, moderate or severe dysplasia or carcinoma in situ), or invasive carcinoma. For example, for a Bethesda System diagnosis of ASCUS, a clinician may have answered that the probability that no disease, CIN 1, CIN 2 or 3, or invasive carcinoma was present was 50%, 40%, 10%, and 0%, respectively. The instructions provided with the questionnaire indicated that for each Bethesda System diagnosis, the combined probability of no disease, CIN 1, CIN 2 or 3, and invasive carcinoma should equal 100%. 17 A cover letter accompanied the questionnaire. 19 The cover letter stated that the questionnaire was voluntary and anonymous. From comments on the pilot questionnaire, it was estimated that the final questionnaire took between 10 and 20 minutes to complete, and this was stated in the cover letter. A return-addressed, postage-paid envelope was enclosed. No compensation was included. The cover letter stated that the responses by the clinicians could result in a better understanding of their perceptions about disease probabilities associated with specific Bethesda System diagnoses.
The questionnaire was mailed to 350 OGYNs and 350 PCPs located in Ohio or Pennsylvania (250 OGYNs and 250 PCPs in Ohio and 100 OGYNs and 100 PCPs in Pennsylvania). [20] [21] [22] The State Board of Medicine of Ohio and the State Board of Medicine of Pennsylvania separated physicians by specialty (OGYNs and PCPs were listed separately), and both boards provided a specified number of physician mailing labels based on a cost per label basis. Both state boards required examination of the questionnaire before sending mailing labels. The specific clinician names used in the mailings of the questionnaire were chosen randomly by the state boards, and the state boards provided no guarantee that the clinicians were still in practice or that their addresses were correct.
Questionnaire responses were analyzed using the statistical analysis program SPSS (SPSS, Chicago, IL). For each demographic and liquid-based cytology question, a mean and SD were calculated, and statistically significant differences between OGYN and PCP responses were determined using a 2-tailed t test. For the probability table, a mean, SD, and range were calculated for each Bethesda System diagnosis and clinician estimation of the probability of disease or no disease. For each probability estimate of disease or no disease associated with each Bethesda System diagnosis, statistical significance between provider types was determined using a 2-tailed t test. For example, statistical significance was determined for the difference between the mean OGYN and the mean PCP probability estimate of no disease for the Bethesda System diagnosis of within normal limits.
To determine whether there was a statistically significant difference between the range of OGYN and range of PCP probability estimates of no disease or disease for each Bethesda System diagnosis, a chi-square test was performed. Statistical significance was assumed when P values were less than or equal to .05.
Results
A total of 27 questionnaires were returned unopened because of an incorrect address, and 31 clinicians returned the questionnaires without responding to the specific questions and wrote that they were no longer practicing medicine. Of the remaining 642 mailed questionnaires, 146 were returned with responses that could be analyzed (overall response rate, 22.7%). The OGYN and PCP response rates were 29.9% (n = 93) and 16.1% (n = 51), respectively. For 2 questionnaires, we could not determine whether the clinician was an OGYN or a PCP.
The clinician and practice demographics for the OGYNs and PCPs are given in ❚Table 1❚. Statistically significant differences were observed for the 2 provider types for the number of cervical vaginal samples (P < .000) and colposcopic biopsies ordered or performed per month (P < .000). In both cases, OGYNs obtained considerably more cervical vaginal samples and ordered or performed more colposcopic biopsies. The percentage of clinicians in private practice was 90.8%.
In ❚Table 2❚, the mean (SD) estimates of the probability of no disease, CIN 1, CIN 2 or 3, and invasive carcinoma for specific Bethesda System diagnoses are given. Data are shown separately for OGYNs and PCPs. For example, the mean PCP estimation that a Bethesda System diagnosis of within normal limits was associated with no disease was 92.8%; in other words, it was estimated that 92.8% of women who had a within normal limits diagnosis would not have a CIN or invasive carcinoma on follow-up (ie, the falsenegative rate would be 7.2%). The mean PCP estimation that a Bethesda System diagnosis of within normal limits was associated with CIN 1 was 6.1%. In general, the larger the SD, the wider the range in individual OGYN or PCP estimates of disease or no disease probabilities.
A 2-tailed t test to determine whether a statistically significant difference existed between the provider types for their estimates of the probability of no disease or disease was performed for each cell in Table 2 , and the cells for which statistical significance was observed are shown in ❚Table 3❚. In total, a statistically significant difference in probability estimates was observed in 7 cells. For example, the difference between the mean OGYN and PCP estimates of no disease for the Bethesda System diagnosis of reactive changes was statistically significant, assuming a 95% confidence level. A type 1 error would be expected in 1.4 cells (28 cells × 0.05), indicating that statistical difference was found in more cells (7) than expected by chance alone (95% confidence).
In ❚Table 4❚, clinician estimates of the probability of no disease or disease given specific Bethesda System diagnoses are given. The probabilities are divided into ranges to illustrate the percentage of clinicians who were outliers based on probability estimates. In Table 4 of clinicians thought that the probability that a woman would have no disease on follow-up was between 90% and 99%; 16.7% of the clinicians thought that the probability that no disease would be detected on follow-up was 100%.
The data in Table 4 show that a number of clinicians estimated relatively high false-negative and false-positive probabilities. For example, 26.9% of clinicians thought the probability of CIN 1, given a within normal limits diagnosis, was 10% or more (4.2% thought that the probability of CIN 1 was greater than 25%). Given a within normal limits diagnosis, 22.3% of clinicians thought that the probability of invasive carcinoma was between 1% and 9%. diagnosis of high-grade SIL, 20.9% of clinicians thought that CIN 2 or 3 would be detected on follow-up in fewer than 25% of cases (6.3% thought that CIN 2 or 3 would be detected on follow-up in fewer than 10% of cases). For the diagnosis of invasive carcinoma, 54.3% of clinicians thought the probability that cancer actually was present was less than 90%. By using a chi-square test, a statistically significant difference between the range of OGYN and range of PCP probability estimates of no disease or disease for specific Bethesda System diagnoses was determined for the following pairs of the Bethesda System diagnoses and disease pairs: within normal limits and invasive carcinoma (P = .030); reactive changes and invasive carcinoma (P = .004); ASCUS and no disease (P = .038); ASCUS and highgrade SIL (P = .012); ASCUS and invasive carcinoma (P = .011); low-grade SIL and invasive carcinoma (P = .009); and high-grade SIL and invasive carcinoma (P = .001).
High variability in the probability estimates of no disease or disease for the Bethesda System diagnoses of ASCUS and AGUS was noted (Table 4) . For the ASCUS diagnosis, 87.5% of clinicians thought that the probability that no disease would be present was greater than 50%. However, 43% of clinicians thought that the probability that cancer would be present given an ASCUS diagnosis was 1% or more. For the diagnosis of AGUS, 19.3% of clinicians thought that the probability of high-grade SIL was 0%; 39.7% of clinicians thought that the probability of cancer was 0%.
Liquid-based cytology was used by 87.8% of clinicians. In answer to the question asking whether liquid-based cytology resulted in an increased sensitivity of SIL detection, 64.3%, 20.5%, and 15.1% of clinicians responded yes, no, and unsure, respectively. In answer to the question asking whether liquid-based cytology was cost-effective, 46.5%, 31.5%, and 21.9% of clinicians responded yes, no, and unsure, respectively. No statistically significant differences were noted in the responses to the liquid-based cytology questions based on practice type, years of experience, number of cervical vaginal samples obtained per month, or number of colposcopic biopsies obtained per month.
❚Table 5❚ shows the cells in which there was a statistically significant difference (using the chi-square statistic; P < .05) in the estimate of no disease, low-grade dysplasia, highgrade dysplasia, and invasive cancer for Bethesda System diagnoses based on years of experience (<10 years, 10-20 years, and >20 years). For example, for the Bethesda System diagnosis of within normal limits and the prediction of no disease, clinicians with fewer than 10 years of experience tended to make a low probability estimate (of no disease) and clinicians with greater than 20 years of experience tended to make a high probability estimate. The overall trend was that clinicians with fewer than 10 years of experience made low probability estimates of no disease for benign diagnoses and high probability estimates of disease for nonbenign diagnoses; the opposite was true for clinicians with more than 20 years of experience. In other words, clinicians with less experience tended to overestimate the probability of dysplasia or invasive cancer.
Discussion
Three broad conclusions may be drawn from these data. The first is that the majority of both OGYNs and PCPs estimated the probability of no disease or disease associated with many Bethesda System diagnoses within the range of Within normal limits <10, low probability; <10, high probability; No statistically significant <10, high probability; >20, high probability >20, low probability difference >20, low probability Reactive changes
No statistically significant No statistically significant <10, high probability; <10, high probability; difference difference >20, low probability >20, low probability ASCUS No statistically significant No statistically significant No statistically significant <10, high probability; difference difference difference >20, low probability AGUS No statistically significant No statistically significant <10, low probability; <10, high probability; difference difference >20, high probability >20, low probability Low-grade SIL <10, high probability; <10, high probability; <10, low probability; <10, high probability; >20, low probability >20, low probability >20, high probability >20, low probability High-grade SIL No statistically significant No statistically significant No statistically significant <10, high probability; difference difference difference >20, low probability Invasive carcinoma <10, high probability; <10, high probability <10, high probability; No statistically significant >20, low probability >20, low probability difference AGUS, atypical glandular cells of undetermined significance; ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; SIL, squamous intraepithelial lesion. * P < .05 was considered statistically significant. Years of experience were divided as follows: <10, 10-20, and >20. Benign indicates no dysplasia or cancer.
probabilities reported in the medical literature ❚Table 6❚. The second is that for a few Bethesda System diagnoses, based on literature data, the majority of clinicians generally were not correct in their probability estimates; the third conclusion is that a subset of clinicians were outliers in the majority of probability estimates.
As a group, the clinicians tended to overestimate the probability of invasive carcinoma associated with most Bethesda System diagnoses except for the diagnosis of invasive carcinoma, which was estimated to have a low probability of invasive carcinoma on follow-up (ie, a high falsepositive rate). This finding was particularly true for the less experienced clinicians, indicating that these clinicians had a tendency to be risk averse to missing a potentially cancerous lesion. On average, clinicians thought that the false-negative rate (ie, a within normal limits diagnosis harboring a CIN or invasive carcinoma) was roughly 7% to 8%.
For some individual clinicians, the probabilities of disease or no disease estimated for some Bethesda System diagnoses differed significantly from the study mean and literature values. For example, for a reactive changes diagnosis, 42 more than 40% of clinicians thought that followup would show a CIN. Other examples may be seen by perusing Tables 4 through 6 . The percentage of clinicians whose probability estimates differed significantly from the study mean was generally less than 20%. Although it is possible that these probability estimates could represent true values in some laboratories or for some patient populations cared for by some clinicians, as a whole, the estimates more likely represent a manifestation of bias.
Leape 44 discussed how biased memory resulted in decisions being based on overgeneralizations; for example, memory may be biased toward overemphasis on the discrepant case. 44, 45 In cervical cancer screening, reported or observed cases of invasive cervical carcinoma in women who received yearly cervical vaginal examinations may result in the overestimation of false negatives. Baron 46 and other authors 8, 9, [47] [48] [49] outlined a number of other biases that affected probability judgments. Dawson 9 described the difficulties that clinicians have in predicting probabilities, and it would seem that some of these difficulties are manifested with the current data. Powsner et al 10 showed that report formatting also may be confusing to some clinicians and may contribute to bias. Although the present study allowed clinicians to use Bayesian decision making, we are uncertain whether the clinicians knew if the probability of disease was related to diagnostic sensitivity. 46 Further study is necessary to examine whether perceptions of disease probability correlate with appropriateness of clinical care. Several authors reported that a percentage of women who had high-risk Bethesda System diagnoses were mismanaged. 11, 12 Other authors argued that women with lower risk Bethesda System diagnoses are overtreated. 50, 51 It is unclear whether overtreatment and undertreatment in cervical cancer screening are secondary to faulty probability judgments.
The Bethesda System diagnoses of ASCUS and AGUS may be viewed as "controversial," although some of this controversy may be secondary to the lack of information or understanding of disease probabilities. 40, 52 The literature indicates that both of these diagnoses have a higher association with CIN, or even invasive carcinoma (particularly AGUS), compared with the diagnoses of reactive changes or within normal limits. 23, 31, 33, 36, 40, 42 However, if more than 20% of clinicians think the probability of disease associated with an ASCUS diagnosis is less than 10% (similar to the mean probability of disease estimated in the present study for a within normal limits diagnosis), some patients may be followed up as though they had a normal smear. On the other hand, with 43% of clinicians estimating the probability of invasive carcinoma associated with an ASCUS diagnosis as greater than 1%, it is no wonder that some women who have an ASCUS diagnosis receive a repeated test in less than 4 months 53 or are given a recommendation to undergo a colposcopic examination. 54, 55 For some Bethesda System categories, compared with mean disease probabilities expressed by PCPs, the mean disease probabilities expressed by OGYNs more accurately reflected literature values. For example, as a group, the PCPs tended to overestimate the probability of invasive carcinoma associated with the diagnoses of ASCUS, low-grade SIL, and high-grade SIL (Tables 3 and 6 ). The OGYNs more accurately predicted the probability of a high-grade dysplasia associated with a high-grade SIL diagnosis. These findings may be explained by the greater familiarity with Bethesda System diagnosis by OGYNs; many OGYNs deal on a daily basis with cervicovaginal screening issues, while PCPs often deal with prevention issues along with many other issues.
Limitations in the present study include the relatively low response rate and the fact that a select clinician population was examined, potentially limiting the generalizability of responses. 15, 16 Some of the study parameters, such as the number of years in practice, were similar to the general means for OGYNs and PCPs reported by the American Medical Association, 56 suggesting that our study sample was not highly skewed. Despite these limitations, these data indicate that a range of clinical perceptions of disease probabilities associated with Bethesda System diagnoses exist and that some of these probability estimates may be biased. Thus, cytologists need to consider that clinicians may misunderstand some Bethesda System reports and that these possible misunderstandings could lead to errors in clinical management. Additional study of how the Bethesda System format may be modified leading to improved clinical understanding is necessary. Alternatively, the greater use of recommendations may be advocated for a certain fraction of practicing clinicians.
